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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the most common primary 
liver malignancy with a rising incidence worldwide, being the sec-
ond cause of cancer death.1 The prognosis of HCC patients is 
poor, and therapies are in most cases only the palliative approach. 
Surgical treatments have more satisfactory results, however, few 
patients can benefit from it. The therapeutic options for HCC of-
ten have more limitations and disappointing results.2,3 In this con-
text, it is urgent to study and develop new therapeutic strategies.
Radiotherapy is one of the most effective anticancer therapies 
and it has been used to treat a wide variety of tumors. The suc-
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Background/Aims: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and it has a poor 
prognosis and few therapeutic options. Radiotherapy is one of the most effective forms of cancer treatment, and P53 
protein is one of the key molecules determining how a cell responds to radiotherapy. The aim of this study was to 
determine the therapeutic efficacy of iodine-131 in three human HCC cell lines. 
Methods: Western blotting was used to measure P53 expression. The effects of radiotherapy with iodine-131 were 
assessed by using the clonogenic assay to evaluate cell survival. Flow cytometry was carried out to examine the effects 
of iodine-131 on cell death, oxidative stress, reduced intracellular glutathione expression, the mitochondrial membrane 
potential, and the cell cycle.
Results: The P53 protein was not expressed in Hep3B2.1-7 cells, was expressed at normal levels in HepG2 cells, and 
was overexpressed in HuH7 cells. P53 expression in the HuH7 and HepG2 cell lines increased after internal and external 
irradiation with iodine-131. Irradiation induced a decrease in cell survival and led to a decrease in cell viability in all of the 
cell lines studied, accompanied by cell death via late apoptosis/necrosis and necrosis. Irradiation with 131-iodine induced 
mostly cell-cycle arrest in the G0/G1 phase. 
Conclusions: These results suggest that P53 plays a key role in the radiotherapy response of HCC. (Clin Mol Hepatol 
2015;21:257-267)
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cess of radiotherapy against cancer depends on its ability to kill 
tumor cells, while preserving the adjacent normal tissue.4,5 Radio-
therapy can be external and internal. In external radiotherapy, the 
device directs rays of high energy to the tumor tissue affecting 
also a small volume of surrounding normal tissue. In internal ra-
diotherapy, the radiation source is placed in/or near the tumor site 
emitting radiation continuously for weeks, months or even one 
year, allowing an higher total dose of radiation to be applied in a 
shorter time than in the external radiotherapy.4,6,7 Several types of 
radiation sources can be used. One of them is beta radiation from 
different radionuclides.6,7 
When, in 1943, radio-iodine was first used in the treatment of 
metastasized thyroid carcinoma, its success in tumor response 
was considered a “miracle”. Since then, many efforts have been 
made to apply radioisotope therapy in other tumors.8 However, 
only a small number of radionuclides have been used to the HCC 
treatment, such as iodine-131, yttrium-90, rhenium-188 and hol-
mium-166 with promising results.9-11
Iodine-131 is a radionuclide, with interesting properties for anti-
cancer therapy. It is available with high radiochemical purity and 
specific activity, has a long half-life of 8.06 days and decays with 
production of beta particles (maximum energy of 606 keV), and 
gamma emissions (main peak at 364 keV).12 
In radiotherapy there are a variety of cellular processes involving 
essential proteins, and which determine the success of treatment. 
The P53 protein is a transcription factor associated with more 
than 50% of human tumors and is a key molecule involved in the 
response to radiotherapy.13,14 It is encoded by the tumor suppres-
sor gene TP53 located on the short arm of chromosome 17 
(17p13.1 locus) and has 393 amino acids and four domains.14,15 
The role of the tumor suppressor genes is to help in the preven-
tion and repair of genetic damage. When cell damage occurs in 
the DNA, and P53 is functional, this protein may induce growth 
arrest, often in G1 or G2 phases of cell cycle, or lead to cell sui-
cide by apoptosis, preventing uncontrolled proliferation and tumor 
development.4,5,13,16 In contrast, if the P53 protein is inactive, 
which can happen by mutation or degradation, DNA damage is 
not detected which leads to a genetic instability. This facilitates 
the initiation and progression of tumors and besides the tumors 
become resistant to chemo and radiotherapy.4,13,14 The resistance 
to radiation appears to be related to germ line P53 mutation, 
however, the association between P53 expression and radiothera-
py response in HCC has not been well studied. Thus, the signifi-
cance of P53 aberration in HCC remains inconclusive.4,5,13
This work aims to investigate the efficiency of iodine-131 radio-
therapy in three HCC cell lines, and the influence of the P53 pro-
tein in the biological mechanisms of HCC. Three human HCC cell 
lines were exposed to different doses of internal or external radia-
tion sources of iodine-131, which differ in P53 expression 17 and 
their viability, cell death and reactive oxygen species (ROS) pro-
duction were as well evaluated.
MATERIAL AND METHODS
Cell culture 
We used three human HCC cell lines: HepG2, HuH7 and 
Hep3B2.1-7. HepG2 and Hep3B2.1-7 cell lines were obtained from 
American Tissue Cell Collection (ATCC), USA. HuH7 cell line was 
obtained from Japanese Collection of Research Bioresources 
(JCRB), Japan. Cells were propagated on adherent cultures in Dul-
becco’s Modified Eagle Medium (DMEM) with 10% Fetal Bovine 
Serum (FBS) (Gibco 2010-09), 100 units/mL of penicillin and 100 
µg/mL of streptomycin (Gibco 15140-122), and incubated at 37°C 
in 5% CO2 atmosphere. 
Irradiation
During the cells exponential growth phase, 5x105 cells were 
exposed to internal and external radiation with iodine-131 (IBA 
Molecular). The conditions used for each irradiation type are out-
lined in Tables 1 and 2. Concerning the internal radiation, the ra-
dionuclide was placed directly in contact with the cells that were 










2,9×10-4 5   1 131I 25
5,5×10-4 5   2 131I 25
1,4×10-3 5   5 131I 25
2,9×10-3 5 10 131I 25
5,5×10-3 5 20 131I 25










4   7   1 131I 25
4 13,6   2 131I 25
4 34   5 131I 25
4 68 10 131I 25
8 68 20 131I 25
259
Ana R. Gomes, et al. 
P53 expression in radiotherapy response: in vitro studies
http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2015.21.3.257
washed afterwards with phosphate buffered saline (PBS). Related 
to the external radiation, a radionuclide source was positioned 
below the flask containing the cells. Doses were calculated as-
suming the worst case scenario, i.e., all the emitted energy in the 
decay process was absorbed by the cells. To calculate the internal 














where D is the absorbed dose (Gy), A0 the initial activity of the 
radioactive source (mCi), T1/2 the half-life time (s), t  the irradia-
tion time (s), Ē the average energy per disintegration (eV) and 
M the mass of the sample subjected to irradiation (kg).
To calculate the external radiation exposure dose, was used 
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P53 and phosphorylated P53 expression  
P53 and phosphorylated P53 protein (p-P53) protein expression 
levels were determined by western blot. Cell extracts were pre-
pared in ice using a solution of radioimmunoprecipitation assay 
(RIPA) buffer and complete Mini Ethylenediamine tetraacetic acid 
(EDTA)-free (Roche). Protein concentrations were determined by 
bicinchoninic (BCA) method. Sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) was held using a 10% 
acrylmide gel. Proteins were electrotransfered to nitrocellulose 
membrane (PVDF) at 4°C, during 1 hour. Membrane blocking was 
performed with 4% bovine serum albumin (BSA) in tris-buffered 
saline tween-20 (TBS-T) for 1 hour at room temperature. Mem-
branes were incubated with primary antibody (P53 or p-P53 or 
β-actin, from Santa Cruz Biotechnology) and secondary antibody 
(mouse antibody, from Sigma) according to the manufacturer’s in-
structions. The blots were stained with elemental chlorine free 
(ECF, Sigma) and read in 9000 Typhoon FLA equipment. 
Cell survival
Cell survival was evaluated using clonogenic assay. Six hundred 
plated cells were irradiated with internal or external source of io-
dine-131 and twelve days afterwards were fixed with methanol 
and stained with crystal violet. Colonies with more than 50 cells 
were counted and the efficiency plate (EP) (relation between the 
number of colonies counted and the number of cells plated) and 
survival factor (SF) (relationship between EP of the treated sample 
and the EP of the control) were determined. 
Flow cytometry
Flow cytometry was used to analyze cell viability, cell death and 
cell cycle as well as to determine ROS and reduced glutathione 
production and mitochondrial membrane potential. All flow cy-
tometry studies used 106 cells per probe and exposures to internal 
or external radiation of 1 or 20 Gy occurred 24 h before the assay. 
For all procedures were performed controls, i.e. cells not subject 
to irradiation.
Cell viability and cell death
The influence of irradiation with iodine-131 on cell viability, and 
the types of induced cell death were determined by flow cytome-
try using annexin-V/propidium iodide (AV/PI) (KIT Immunotech). 
One of the main features of cell death by apoptosis is the redistri-
bution of plasma membrane phosphatidylserine, a phospholipid 
that, in apoptotic cells, is translocated from the inner to the outer 
leaflet of the plasmatic membrane and binds to AV. Complemen-
tarily, PI, which does not permeate viable cells, binds to deoxyri-
bonucleic acid (DNA) intercalating between the bases on late 
apoptotic and necrotic cells.18 In this assay, 106 cells were incubat-
ed during 15 min in binding buffer with 1 µL of AV (Kit Immuno-
tech) and 5 µL of PI (Kit Immunotech). Subsequently, cells were 
excited at a wavelength of 525 nm for AV and 640 nm for PI, col-
lecting 104 events to assess the percentage of viable, early apop-
totic, late apoptotic/necrotic, and necrotic cells.18
Evaluation of ROS and reduced glutathione production, 
mitochondrial membrane potential and cell cycle
ROS production: intracellular peroxide were measured using 
2’,7’-dichlorodihydrofluorescein diacetate (DCFH2-DA, Invitrogen); 
intracellular superoxide was determined using the dihydroethidium 
probe (DHE, Sigma). Expression of intracellular reduced glutathione 
was evaluated with mercury orange (GSH, Sigma). Mitochondrial 
membrane potential was analyzed with 5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethylbenzimidazol carbocyanine (JC-1, Invitrogen). Cell 
cycle was evaluated with PI/RNase solution (Immunostep). Assays 
were performed according to a method described by Mamede et 
al.18 Results are presented as mean fluorescence intensity (MFI). 
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Statistical analysis
Cell survival curves were obtained using Origin Pro v8.0, fitting 
the experimental data to two models: for lower doses, the data 
was fitted to a linear-quadratic model, according to the equation 
SF=e-αD-βD2; for higher radiation doses, we fitted the data to a 
linear model, using SF=e-C-αD. These two models were chosen as 
they fitted the data when used together. P53, p-P53 expression, 
and all flow cytometry results were analyzed using IBM SPSS® v.19 
(IBM Corporation, Armonk, New York, USA). In the descriptive 
analysis measures of central tendency (mean and median) and 
dispersion (standard deviation and interquartile range) were ob-
tained for quantitative variables. To assess normality of the distri-
bution of quantitative variables, Shapiro-Wilk’s test was used. 
Parametric tests were used for comparisons in the case normality 
was observed; in the opposite case we used nonparametric tests. 
For comparison of quantitative variables between two groups we 
used Student’s t test (parametric) or Mann-Whitney’s test (non-
parametric). For more than two groups we used one factor Analysis 
of Variance (ANOVA) test, with post-hoc Tukey test (parametric) or 
Kruskal-Wallis test with multiple comparisons performed using the 
Mann-Whitney’s test with Bonferroni correction (nonparametric). 
For all comparisons a significance level of 5% was considered.
RESULTS
P53 and phosphorylated P53 expression 
Basal P53 expression differs significantly across the three HCC 
cell lines studied (Fig. 1). P53 expression, as determined by west-
ern blotting, demonstrated to be highest in HuH7 cell line 
(0.48%), and null in Hep3B2.1-7 cells (0%).  When HuH7 and 
HepG2 cell lines were exposed to the treatment with iodine-131, 
it was observed a gradual increase in P53 expression with the 
dose and with the time after irradiation as demonstrated in Fig-
ure 2. The HuH7 cells showed the highest levels of P53 expres-
sion (P<0.05), regardless of the dose and exposure duration of 
radiation, in comparison to HepG2 cell line. The P53 expression 
was higher, 24 hours after exposure at 20 Gy, both for internal or 
external radiation (P<0.05). For all doses and exposure duration 
tested, the levels of P53 protein expression were higher after ex-
ternal radiation. 
Phosphorylated P53 expression was present in all cell lines ex-
posed to iodine-131 at 20 Gy for 24 hours, being higher after ex-
ternal irradiation compared to internal radiation (Fig. 3). HepG2 
cells showed the highest levels of p-P53, with 1.99% of protein 
expression (P=0.002).
Cell survival, cell viability and cell death 
The increasing exposure to radiation doses, led to a reduction 
in cell survival as represented in Figure 4. The HuH7 cells were the 
most radiosensitive to the internal irradiation for high doses, and 
HepG2 cells to the external irradiation, showing a greater reduc-
tion of cell survival. The Hep3B2.1-7 cells were the less radiosensi-
tive to the both irradiation types.
Using internal irradiation, HepG2 cells showed 49% of viability 
(P =0.031), and a tendency to activate cell death by necrosis 
(P=0.03) at 20 Gy (Fig. 5). The HuH7 cells had 59% of viability af-
ter 1 Gy of irradiation, and 20% of cells died by apoptosis 
(P=0.02). The Hep3B2.1-7 cells had 49% of viability, and 24% 
died by apoptosis (P=0.003), after internal irradiation with 20 Gy. 
After 1 Gy external irradiation, the HepG2 cells had 40% of viabil-
ity (P=0.013), and 28% of viability at 20 Gy (P=0.001). Regarding 
cell death, 32% of Hep3B2.1-7 cells died by necrosis with 1 Gy ir-
radiation dose (P=0.017), and at 20 Gy, 25% died by late apopto-
sis/necrosis (P=0.016), and 35% by necrosis (P=0.031) (Fig. 5). 
The HuH7 cells showed 17% of death by late apoptosis/necrosis 
at 1 Gy and 20% at 20 Gy. The Hep3B2.1-7 cells had 49% of via-
bility (P=0.036), 19% dying by late apoptosis/necrosis (P=0.024) 
and 20% by necrosis (P=0.046) at 20 Gy.
Figure 1. Evaluation of basal P53 protein expression. Bands correspond-
ing to P53 (53 kDa) and actin protein (47 kDa) in the HepG2, HuH7, and 
Hep3B2.1-7 cell lines. Data are mean and SE values (n=6). Hashes indicate 
statistically significant differences between the conditions (P<0.05).
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ROS and reduced glutathione production, 
mitochondrial membrane potential and cell cycle 
Regarding to the intracellular peroxide concentrations in cells 
exposed to internal 1 Gy irradiation was observed an increase in 
intracellular peroxide concentration in Hep3B2.1-7 cell line 
(P=0.015), relative to control cell population (Fig. 6A). Similarly, in 
the external irradiation, it was observed, for the same irradiation 
dose, an increase in intracellular peroxide concentration in HuH7 
Figure 2. Evaluation of P53 protein expressions in HepG2 and HuH7 cell lines in response to internal irradiation (IR)  and external irradiation (ER) with 
different doses of iodine-131 and for different exposure durations. Data are mean and SE values (n=5). Asterisks indicate statistically significant differ-
ences compared to controls (P<0.05).
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cells (P=0.013) as well as for 20 Gy (P=0.016), in comparison to 
control. The intracellular reduced glutathione concentration ex-
posed to 1Gy external irradiation, increased in Hep3B2.1-7 cells 
(P=0.016), in comparison to control.
Comparing both irradiation types, there was a general tendency 
for a higher increase of ROS production especially in intracellular 
peroxide concentrations in HuH7 for 1 Gy (P=0.018) and 20 Gy 
(P=0.021) irradiation doses, and in superoxide radical concentra-
tion in HepG2 only for 1 Gy irradiation dose (P=0.046). Concern-
ing glutathione production it was observed a decrease especially 
in Hep3B2.1-7 cell line after 1 Gy irradiation dose (P=0,027) as 
well as for mitochondrial membrane potential in which it was ob-
served a decreased comparing the external with the internal irra-
diation results (Fig. 6A)
The results obtained in the cell cycle study showed that, com-
pared with the control and regardless of cell line, dose and irradi-
ation type used, the cell cycle was mostly arrested in G0/G1 phase 
(Fig. 6B). Moreover, arrest in G0/G1 phase was more evident in 
cells externally irradiated than in cells internally irradiated, for 
HuH7 and Hep3B2.1-7 cells. The HuH7 cells were the most sensi-
tive. 
DISCUSSION
Worldwide, HCC is the second leading cause of cancer-related 
death.1 Overall survival at 5 years for patients with HCC is approx-
imately 2-10%, so it is urgent to develop new therapeutic strate-
gies for this highly aggressive cancer.3 Radiotherapy is one of the 
most effective forms of cancer treatment and P53 is a key mole-
cule involved in cellular response to ionizing radiation.5,13,14,19
Given the importance of P53 expression in the development 
and response to treatment of many types of tumors, and in order 
to determine the effectiveness of radiotherapy in different HCC 
cell lines, we evaluated the P53 expression protein in three HCC 
Figure 3. Evaluation of phosphorylated P53 protein expressions in 
HepG2 and HuH7 cell lines in response to IR and ER with different doses 
of iodine-131 and for different exposure durations. Data are mean and SE 
values (n=3). Asterisks indicate statistically significant differences com-
pared to controls (P<0.05).
Figure 4. Cell survival curves for HepG2, HuH7, and Hep3B2.1-7 cell lines 
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cell lines. One of the biochemical features which differ between 
these cell lines is the P53 expression levels. Thus, in response to 
radiotherapy the cell lines used showed differences in P53 protein 
expression. HuH7 and HepG2 had a basal P53 protein expression. 
The Hep3B2.1-7 cell line, which has a homozygous deletion in 
exon 11 of the TP53 gene, does not have the ability to express 
P53 protein.20-31 HepG2 cells, express P53 at intermediate level 
comparatively to HuH7 and Hep3B2.1-7 cell lines, as reported in 
literature.21,23,26,31 As expected and also described in literature by 
Reiser et al.26 and Bressac et al.,23 mutated P53 at codon 220 cys-
tyr of exon 6 in HuH7 cells, induces an overexpression of this pro-
tein.22,25 Hep3B2.1-7 cell line did not express P53, and thus the 
expression of this protein in response to irradiation was not evalu-
ated. But after internal and external radiation exposure, differenc-
es in P53 expression in HepG2 and HuH7 cells were observed. 
When comparing the P53 protein expression levels in HepG2 and 
HuH7 cell lines, using internal or external irradiation, the cell line 
that showed higher P53 expression was HuH7. Thus, we can con-
firm the P53 protein overexpression in HuH7 cells, as described in 
the literature.23,26 It was also found that, independently of cell 
line, for all doses and exposure duration, P53 protein expression 
was higher in external comparing with the radiation internal ex-
posure.
In order to confirm if P53 protein was active after irradiation in 
HepG2 and HuH7 cell lines, phosphorylated P53 expression was 
evaluated for 24 hours exposure duration and 20 Gy dose. It was 
verified that the P53 protein was active in both cell lines, but 
more active when exposed to external radiation than internal ra-
diation, which is coincident with P53 expression. Thus, the cell 
lines exposed to external radiation have a greater ability to repair 
cellular damage.
After verifying that the P53 expression was largely affected by 
Figure 5. Cell viability analysis using flow cytometry with AnV/IP double staining. The results are percentages of cells that are viable, in apoptosis, in 
late apoptosis/necrosis, and in necrosis at 24 hours after IR or ER with iodine-131. Data are mean and SE values (n=8). Asterisks indicate statistically sig-
nificant differences compared to controls (P<0.05).
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Figure 6. Figure 6. (a) Flow cytometry analysis of the production of intracellular peroxides and superoxide radicals, and of reduced intracellular gluta-
thione expression and the mitochondrial membrane potential. Data are mean and SE values (n=8). Asterisks and hashes respectively indicate statisti-
cally significant differences compared to controls and between IR and ER (P<0.05). (b) Cell-cycle analysis in the HepG2, HuH7, and Hep3B2.1-7 cell lines 
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the exposure to iodine-131, cell survival and cell viability were 
evaluated. As described in the literature by Gudkov and Koma-
rova,4 “…P53 can be a determinant of radiosensitivity”. The dif-
ferences in radiosensitivity between cell lines are due the different 
levels of P53 expression: the most radiosensitive cell lines were 
those that exhibited a higher expression of P53, which is support-
ed by a greater decrease on cell survival (HepG2 e HuH7). Allow-
ing them, a greater ability to recognize cellular damage, than 
Hep3b2.1-7 cells.4,5,14 So, cell survival after treatment with io-
dine-131 might be influenced by P53 expression. The internal ra-
diation is a little more aggressive than the external radiation, like-
ly due to the direct exposure of cells to beta particles and gamma 
rays, while in the external radiation, the cells were exposed only 
to gamma rays.
It was expected that P53 protein triggered mostly apoptotic cell 
death.4,5,16,32,33 However, HepG2, HuH7 and Hep3B2.1-7 cells died 
by late apoptosis/necrosis and necrosis.34 Necrosis is triggered as 
a response to high dose radiation. Therefore, we must take into 
account the aggressiveness of radiation to which cells were sub-
jected in the treatment with iodine-131, and the studies were per-
formed 24 hours after treatment. Moreover, we cannot exclude 
the possibility that we observed a late stage in cell death path-
way, which could initially or earlier have been apoptosis or au-
tophagy or mitotic death.35
Through the observation of Figure 5, it appears that the HepG2 
cell line is more sensitive to both the treatments used (internal 
and external irradiation) than HuH7 cell line. This result may be 
related to the fact that the HepG2 cell line express the normal and 
functional form of P53,17 thereby recognizing the damage caused 
and triggering a cell death process. In fact it is widely recognized 
the key role that P53 plays in the process of apoptosis, however, 
some studies have shown that P53 also has a leading role in ne-
crosis,35,36 which reinforces the obtained results .
ROS are involved in a variety of cellular processes, including cell 
growth arrest or cell death. ROS are mainly produced in the body by 
exposure to ionizing radiation, and high concentrations of ROS cause 
cell death preferably by necrosis.38-40 In this study it was found some 
necrotic cell death and high levels of cell growth arrest.38-40 
As expected and described in the literature by Gudkov and Ko-
marova,4 Begg et al.5 and Levine and Oren,13 the phase of cell cy-
cle in which there was higher cell growth arrest was the G0/G1 
phase, being more evident for the highest dose (20 Gy), since very 
high doses induce higher activation of the P53 protein, responsi-
ble for cell growth arrest.4,5,13,14,16 It should also be observed that 
the levels of cell growth arrest were higher with external radia-
tion, which was likely due to the aggressiveness of direct expo-
sure of cells to beta particles and gamma rays, which causes ad-
ditional cell stress and prohibits activation of the P53 protein.14,41 
Reported by several researchers as a key molecule involved 
in cell response to ionizing radiation, the study of P53 protein 
in this experimental work was of high importance.4,5,13,14 Coin-
cident with various studies one of main findings is that cells 
expressing P53 in larger quantities were the most radiosensi-
tive (decreased viability), which is consistent with previously 
published reports on P53 protein expression in response to ra-
diotherapy. This may implicate a more favorable prognosis for 
tumors which express this gene.4,5,14 Thus, we conclude that 
the TP53 tumor suppressor might be a key factor in response 
to radiotherapy.5,13 Another important message from this work 
is that the molecular profile of tumors should be explored in 
great detail, to try to predict the response of tumor cells to 
various therapeutic approaches. The signaling pathways in-
volved in each mechanism of tumor development must be in-
vestigated, because the assessment of one protein does not 
provide a thorough understanding of the mechanisms of cellu-
lar response and, therefore, further investigation should be 
performed. The P53 mutations are one of the most significant 
alterations in cell regulation, which can lead to the develop-
ment of HCC. Thus, we believe that this research is important 
for a better evaluation of clinical prognostic and development 
of therapeutic strategies that ensure a better patient survival.
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